What did Benchmark change in the HALO analyst rating on February 03, 2026?

Benchmark maintained a **Buy** rating on February 03, 2026, after Halozyme raised FY25 revenue guidance to **$1.385–$1.40 billion**. The firm did not publish a new price target in the public note.

Does the Benchmark action include a new HALO price target?

No. The published Benchmark summary reiterated Buy but did not list a specific new price target. The report focused on raised guidance as the justification.

How should investors interpret a maintained Buy in HALO analyst rating terms?

A maintained Buy signals continued analyst confidence without a change in conviction. It supports further upside if guidance trends continue, but investors should still assess valuation and downside risk.

What is Meyka AI’s current grade for HALO and what does it mean?

Meyka AI rates HALO with a grade of **B+**. This grade factors in S&P 500 benchmarking, sector performance, financial growth, key metrics, and analyst consensus. It is informational, not financial advice.

Analyst Ratings

Benchmark Maintains Buy on HALO (Halozyme Therapeutics, Inc.) Feb 2026

ByDanny Kontos February 4, 2026

Benchmark maintained a Buy rating on Halozyme Therapeutics, Inc. (HALO) on February 03, 2026, a clear HALO analyst rating reiteration after the company raised FY25 guidance. The note appeared at 09:29 AM and Benchmark cited stronger revenue outlook as the driver. Benchmark’s move left no new price target in the published note. The stock showed a short-term uptick of 0.83% ($0.63) on the news. Meyka AI rates HALO with a grade of B+ for its relative strength, sector positioning, and analyst consensus.